113 results on '"Kratz, Jeremy D."'
Search Results
2. Understanding futility in pancreaticoduodenectomy: Insights from a national cohort.
3. Carboplatin and Paclitaxel Chemoradiation for Localized Anal Cancer in Patients Not Eligible for Mitomycin and 5-Fluorouracil.
4. Survival impact of homologous recombination deficiency in veterans with cholangiocarcinoma including mutual exclusivity with pathogenic KRAS and TP53.
5. Actionable molecular alterations in veterans with advanced cholangiocarcinoma.
6. Neoadjuvant SBRT plus regional nodal irradiation with concurrent capecitabine for patients with resectable pancreatic cancer: Survival analysis of prospective phase 1 trial.
7. Molecular Targets and Therapies for Ampullary Cancer
8. Treatment of Oligometastatic GI Cancers
9. Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases
10. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
11. Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection
12. CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
13. Abstract 5327: Automated organoid alignment for clonal response characterization in pancreatic ductal adenocarcinoma
14. Data from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
15. Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
16. Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
17. Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer
18. Abstract A073: Multiplexed therapeutic sensitivity of patient derived pancreatic cancer organoids after neoadjuvant chemotherapy by high content imaging
19. Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice
20. Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers.
21. Atherosclerosis and Nanotechnology: Diagnostic and Therapeutic Applications
22. Technologies to Assess Drug Response and Heterogeneity in Patient-Derived Cancer Organoids
23. Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
24. Metastatic bulk to predict subclonal heterogeneity by ctDNA in RAS/RAF-wildtype colorectal cancer.
25. Prognostic impact of common pathologic alterations in pancreatic ductal adenocarcinoma from the veterans health administration.
26. Challenges in biomarker-based clinical trials for patients with gastrointestinal malignancies
27. Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
28. Impact of baseline culture conditions of mouse-derived cancer organoids when determining therapeutic response and tumor heterogeneity
29. Sensitivity of HER2-amplified colorectal organotypic cancer spheroids at ex vivo resistance to panitumumab and trastuzumab.
30. Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma
31. Abstract B27: MTORC1/2 inhibition as a treatment strategy for PIK3CA mutant colorectal cancer
32. Abstract 2701: Patient-derived colorectal cancer organoid therapeutic escalation: Tracking resistance to EGFR inhibition for predicting therapeutic sensitivity
33. Abstract 1494: Etiologies of patient-derived colorectal cancer organoid growth heterogeneity across multiple patient samples and culture conditions
34. Efficacy of single-agent epidermal growth factor receptor inhibition in the second-line setting for metastatic colorectal cancer with a goal towards retreatment strategies.
35. Effect size as a tool to identify subpopulations with improved clinical outcomes in metastatic colorectal cancer.
36. Defining population response of patient-derived colorectal cancer organoids against prospective clinical outcomes.
37. The evolving treatment paradigm for BRAF V600 mutant colorectal cancer
38. Abstract 3143: Predicting treatment response using patient derived organotypic cancer spheroids
39. Utility of effect size to define populations with durable clinical outcomes across trials of metastatic colorectal cancer.
40. Patient-derived colorectal cancer spheroids for single cell characterization of intratumor heterogenity in response to EGFR inhibition.
41. MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
42. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer
43. Tumor bulk to predict clinical outcomes of anti-EGFR therapy in treatment refractory metastatic colorectal cancer independent of sidedness.
44. Molecular Profiles Guide Colorectal Cancer Treatment
45. Tumor bulk as an independent marker of anti-EGFR therapeutic benefit in metastatic colorectal cancer.
46. Gynaecomastia in two men on stable antiretroviral therapy who commenced treatment for tuberculosis
47. Design considerations for PAMAM dendrimer therapeutics
48. Long-term follow-up results of ipilimumab and nivolumab for the treatment of mismatch repair deficient locally advanced rectal cancer.
49. High rates of detection of metastatic/recurrent colorectal cancer on clinical imaging at the time of molecular residual disease testing following operative management.
50. Carboplatin and paclitaxel chemoradiation for localized anal cancer in patients not eligible for mitomycin and 5-fluorouracil.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.